GlassScriptPhysician profile
Blake Anthony Williams
NPI 1194082057
$10,291.51
in general payments reported to CMS, 2019-2025
32 companies · $1,701 in 2025
The $1,701 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,159 · 2020: $867 · 2021: $1,178 · 2022: $1,572 · 2023: $1,065 · 2024: $1,750 · 2025: $1,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,284 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,284.22 |
| Education | $231.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,932.81 | 2019-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $1,445.88 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Allergan, INC. | $1,231.99 | 2019-2022 | |
| Janssen Biotech, INC. | $1,183.25 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $579.09 | 2019-2025 | Odomzo, Blu-U, Winlevi |
| Genzyme Corporation | $541.53 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $539.99 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $480.24 | 2022-2024 | Sotyktu |
| Pfizer INC. | $393.14 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $349.98 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $330.32 | 2020-2025 | Bimzelx |
| Leo Pharma INC. | $212.38 | 2023-2025 | Adbry, Anzupgo |
| Amgen INC. | $175.73 | 2019-2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $135.23 | 2019-2024 | Siliq |
| Sanofi-Aventis U.S. LLC | $114.94 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $108.91 | 2022 | |
| Galderma Laboratories, L.P. | $97.75 | 2024-2025 | Nemluvio |
| Dermira, INC. | $60.85 | 2019-2021 | |
| Genentech USA, INC. | $51.07 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $46.61 | 2019-2025 | |
| Dusa Pharmaceuticals, INC. | $40.41 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $38.69 | 2019 | |
| Almirall LLC | $25.28 | 2021 | |
| Incyte Corporation | $24.69 | 2025 | Opzelura |
| Kyowa Kirin, INC. | $23.50 | 2023 | Poteligeo |
| Dexcom, INC. | $22.66 | 2025 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $21.60 | 2022 | |
| Aclaris Therapeutics, INC. | $21.12 | 2019 | |
| Biofrontera INC. | $19.22 | 2022 | |
| Vyne Pharmaceuticals INC. | $19.13 | 2020 | |
| Arcutis Biotherapeutics, INC. | $17.17 | 2025 | Zoryve |
| Organon LLC | $6.35 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.